Jay D. Rosenbaum’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-4,180
| Closed | -$422K | – | 51 |
|
|
2023
Q4 | $422K | Sell |
4,180
-4,375
| -51% | -$422K | 1.09% | 37 |
|
|
2023
Q3 | $871K | Buy |
8,555
+300
| +4% | +$30.5K | 1.46% | 32 |
|
|
2023
Q2 | $833K | Buy |
8,255
+306
| +4% | +$30.6K | 1.34% | 33 |
|
|
2023
Q1 | $731K | Buy |
7,949
+959
| +14% | +$83.8K | 1.35% | 34 |
|
|
2022
Q4 | $634K | Sell |
6,990
-944
| -12% | -$79.5K | 1.37% | 35 |
|
|
2022
Q3 | $603K | Buy |
7,934
+61
| +0.8% | +$5.06K | 1.39% | 32 |
|
|
2022
Q2 | $666K | Sell |
7,873
-877
| -10% | -$76.9K | 1.29% | 34 |
|
|
2022
Q1 | $768K | Buy |
8,750
+370
| +4% | +$32K | 1.21% | 34 |
|
|
2021
Q4 | $733K | Sell |
8,380
-357
| -4% | -$29.6K | 1.08% | 39 |
|
|
2021
Q3 | $714K | Buy |
8,737
+275
| +3% | +$24.7K | 1.19% | 38 |
|
|
2021
Q2 | $773K | Buy |
8,462
+590
| +7% | +$52.5K | 1.28% | 35 |
|
|
2021
Q1 | $673K | Buy |
7,872
+422
| +6% | +$37.9K | 1.15% | 37 |
|
|
2020
Q4 | $703K | Buy |
7,450
+725
| +11% | +$63.4K | 1.22% | 34 |
|
|
2020
Q3 | $585K | Buy |
6,725
+205
| +3% | +$17.8K | 1.08% | 37 |
|
|
2020
Q2 | $569K | Hold |
6,520
| – | – | 1.12% | 35 |
|
|
2020
Q1 | $537K | Buy |
6,520
+508
| +8% | +$45.3K | 1.24% | 32 |
|
|
2019
Q4 | $569K | Sell |
6,012
-68
| -1% | -$6.1K | 1.01% | 40 |
|
|
2019
Q3 | $529K | Buy |
6,080
+330
| +6% | +$29.6K | 1.01% | 40 |
|
|
2019
Q2 | $525K | Sell |
5,750
-645
| -10% | -$54.6K | 1% | 43 |
|
|
2019
Q1 | $551K | Buy |
6,395
+84
| +1% | +$6.74K | 1.04% | 41 |
|
|
2018
Q4 | $485K | Sell |
6,311
-167
| -3% | -$13K | 1.03% | 41 |
|
|
2018
Q3 | $500K | Buy |
6,478
+16
| +0.2% | +$1.18K | 0.91% | 43 |
|
|
2018
Q2 | $437K | Buy |
6,462
+73
| +1% | +$5.04K | 0.86% | 43 |
|
|
2018
Q1 | $463K | Hold |
6,389
| – | – | 0.94% | 38 |
|
|
2017
Q4 | $481K | Buy |
6,389
+84
| +1% | +$6.34K | 0.89% | 37 |
|
|
2017
Q3 | $485K | Buy |
6,305
+312
| +5% | +$23.6K | 0.93% | 38 |
|
|
2017
Q2 | $448K | Buy |
5,993
+698
| +13% | +$49.5K | 0.89% | 41 |
|
|
2017
Q1 | $352K | Buy |
5,295
+1,116
| +27% | +$74.4K | 0.75% | 40 |
|
|
2016
Q4 | $273K | Buy |
4,179
+781
| +23% | +$50.7K | 0.63% | 41 |
|
|
2016
Q3 | $240K | Buy |
3,398
+111
| +3% | +$8.09K | 0.03% | 46 |
|
|
2016
Q2 | $243K | Buy |
+3,287
| New | +$227K | 0.03% | 47 |
|
Other funds holding NVS
Jay D. Rosenbaum's NVS Position: Q1 2024 in Review
Jay D. Rosenbaum sold out of Novartis (NVS) in Q1 2024, closing a stake of 4,180 shares — an estimated $422K sold.
Jay D. Rosenbaum first reported a position in NVS in Q2 2016 and held it in 31 quarters. The position peaked at $871K in Q3 2023. 1,254 funds tracked by Wall St. Rank hold NVS as of Q1 2024.
- Jay D. Rosenbaum reported no remaining Novartis position as of Q1 2024 after selling out during the quarter.
- Jay D. Rosenbaum sold 4,180 Novartis shares in Q1 2024, an estimated $422K.
- Jay D. Rosenbaum first reported a position in Novartis in Q2 2016 and held it in 31 quarters.
- Jay D. Rosenbaum's Novartis position peaked at $871K in Q3 2023.
- 1,254 funds tracked by Wall St. Rank held Novartis as of Q1 2024.
Based on Jay D. Rosenbaum's 13F filing for Q1 2024, filed 15 May 2024.